Abstract:Summary Background The diagnosis of cardiac amyloidosis can be established non-invasively by scintigraphy using bone-avid tracers, but visual assessment is subjective and can lead to misdiagnosis. We aimed to develop and validate an artificial intelligence (AI) system for standardised and reliable screening of cardiac amyloidosis-suggestive uptake and assess its prognostic value, using a multinational database of 99m Tc-scintigraphy data across multiple tracers and scanners. Methods In this retrospective, international, multicentre, cross-tracer development and validation study, 16 241 patients with 19 401 scans were included from nine centres: one hospital in Austria (consecutive recruitment Jan 4, 2010, to Aug 19, 2020), five hospital sites in London, UK (consecutive recruitment Oct 1, 2014, to Sept 29, 2022), two centres in China (selected scans from Jan 1, 2021, to Oct 31, 2022), and one centre in Italy (selected scans from Jan 1, 2011, to May 23, 2023). The dataset included all patients referred to whole-body 99m Tc-scintigraphy with an anterior view and all 99m Tc-labelled tracers currently used to identify cardiac amyloidosis-suggestive uptake. Exclusion criteria were image acquisition at less than 2 h ( 99m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid, 99m Tc-hydroxymethylene diphosphonate, and 99m Tc-methylene diphosphonate) or less than 1 h ( 99m Tc-pyrophosphate) after tracer injection and if patients' imaging and clinical data could not be linked. Ground truth annotation was derived from centralised core-lab consensus reading of at least three independent experts (CN, TT-W, and JN). An AI system for detection of cardiac amyloidosis-associated high-grade cardiac tracer uptake was developed using data from one centre (Austria) and independently validated in the remaining centres. A multicase, multireader study and a medical algorithmic audit were conducted to assess clinician performance compared with AI and to evaluate and correct failure modes. The system's prognostic value in predicting mortality was tested in the consecutively recruited cohorts using cox proportional hazards models for each cohort individually and for the combined cohorts. Findings The prevalence of cases positive for cardiac amyloidosis-suggestive uptake was 142 (2%) of 9176 patients in the Austrian, 125 (2%) of 6763 patients in the UK, 63 (62%) of 102 patients in the Chinese, and 103 (52%) of 200 patients in the Italian cohorts. In the Austrian cohort, cross-validation performance showed an area under the curve (AUC) of 1·000 (95% CI 1·000–1·000). Independent validation yielded AUCs of 0·997 (0·993–0·999) for the UK, 0·925 (0·871–0·971) for the Chinese, and 1·000 (0·999–1·000) for the Italian cohorts. In the multicase multireader study, five physicians disagreed in 22 (11%) of 200 cases (Fleiss' kappa 0·89), with a mean AUC of 0·946 (95% CI 0·924–0·967), which was inferior to AI (AUC 0·997 [0·991–1·000], p=0·0040). The medical algorithmic audit demonstrated the system's robustness across demographic factors, tracers, scanners, and centres. The AI's predictions were independently prognostic for overall mortality (adjusted hazard ratio 1·44 [95% CI 1·19–1·74], p<0·0001). Interpretation AI-based screening of cardiac amyloidosis-suggestive uptake in patients undergoing scintigraphy was reliable, eliminated inter-rater variability, and portended prognostic value, with potential implications for identification, referral, and management pathways. Funding Pfizer.

Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis

Artificial Intelligence Applied to Electrocardiographic Images for Scalable Screening of Transthyretin Amyloid Cardiomyopathy

Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms

Tracking the pre-clinical progression of transthyretin amyloid cardiomyopathy using artificial intelligence-enabled electrocardiography and echocardiography

Detection of ATTR cardiac amyloidosis using a novel artificial intelligence algorithm for wearable-adapted noisy single-lead electrocardiograms

Interpretable artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

Evaluating the performance and potential bias of predictive models for the detection of transthyretin cardiac amyloidosis

Diagnosis of hypertrophic cardiomyopathy by artificial intelligence using standard transthoracic echocardiography

Artificial intelligence-guided detection of under-recognized cardiomyopathies on point-of-care cardiac ultrasound: a multi-center study

Artificial intelligence (AI)-enhanced electrocardiography: a machine-learning model for differential diagnosis between hypertrophic cardiomyopathy, cardiac amyloidosis and Anderson-Fabry disease

Artificial Intelligence Assists in the Early Identification of Cardiac Amyloidosis

Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis

Artificial intelligence-enhanced electrocardiogram for the diagnosis of cardiac amyloidosis: A systemic review and meta-analysis

Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis

Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study

Multimodal Fusion of Echocardiography and Electronic Health Records for the Detection of Cardiac Amyloidosis

Automated Echocardiographic Detection of Heart Failure With Preserved Ejection Fraction Using Artificial Intelligence

Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study

Detection and risk stratification of cardiac amyloidosis patients by integration of imaging and non-imaging data using a machine learning approach

Artificial intelligence-based myocardial texture analysis in etiological differentiation of left ventricular hypertrophy